Cardiovascular, metabolic, and mortality outcomes with semaglutide versus tirzepatide in obese patients with hypothyroidism: a real-world analysis

Authors

• Andrew Cecil, Advocate Health - MidwestFollow
• Ekow Essien, Advocate Health - MidwestFollow
• Abena Agyekum
• Gloria Amoako

Recommended Citation

Cecil A, Essien E, Agyekum A, Amoako G. Cardiovascular, metabolic, and mortality outcomes with semaglutide versus tirzepatide in obese patients with hypothyroidism: a real-world analysis. Endocrine Practice. 2026;32(4, Supplement):S352. doi:10.1016/j.eprac.2026.03.054

Presentation Notes

Corresponding poster presentation available at: https://institutionalrepository.aah.org/auroragme/839/

Type

Abstract